文献速递糖尿病

在意大利单中心TrialNet预防路径研究中筛查胰岛自身抗体并随访的1型糖尿病亲属中糖尿病酮症酸中毒的预防

Prevention of diabetic ketoacidosis in relatives screened for islet autoantibodies and followed up in the TrialNet Pathway to Prevention study at a single institution in Italy.
PubMed 文献 · Diabetologia · 2025-05-29

该单中心观察性研究在意大利米兰圣拉斐尔医院筛查4046名1型糖尿病亲属的胰岛自身抗体,中位随访9.9年,51名(1.6%)进展至3期,疾病起病时未记录到糖尿病酮症酸中毒发生。

要点

  • 首次筛查时4.9%自身抗体阳性,其中3.1%为单一抗体、1.8%为多种抗体。
  • 自身抗体阴性、单阳性、多阳性者疾病发生率分别为0.4%、6.5%、43.1%(p=0.012)。
  • 疾病起病时未记录到糖尿病酮症酸中毒发生,中位静脉pH为7.37。

核心结论

  • 通过单中心自身抗体筛查联合定期监测的早期识别方法,在1型糖尿病亲属中完全预防了疾病起病时的糖尿病相关酮症酸中毒。

研究设计与样本

  • 单中心观察性研究,在意大利米兰圣拉斐尔医院开展,属于国际多中心TrialNet自然史研究-预防路径的一部分。
  • 筛查对象为1型糖尿病患者的亲属:一级亲属年龄1-45岁,二级亲属年龄1-20岁。
  • 主要筛查谷氨酸脱羧酶抗体(GADA)、胰岛素自身抗体(IAA)和蛋白酪氨酸磷酸酶2抗体(IA-2A);阳性者后续检测胰岛细胞抗体(ICA)和锌转运体8抗体(ZnT8A)。
  • 对自身抗体阳性参与者提供定期自身抗体检测、代谢监测和教育支持。
  • 筛查时间为2005年7月至2020年2月,最新随访更新时间为2023年1月至2024年6月。

主要发现

  • 共筛查4046名亲属,筛查时中位(IQR)年龄为17.6(7.9-38.0)岁。
  • 首次筛查时4.9%为自身抗体阳性,其中3.1%为单一自身抗体、1.8%为多种自身抗体。
  • 78.5%的参与者有随访数据,中位(IQR)随访时间为9.9(6.5-13.5)年。
  • 51名(1.6%)参与者进展至3期;自身抗体阴性、单阳性、多阳性参与者的疾病发生率分别为0.4%、6.5%、43.1%,中位(IQR)起病时间分别为7.8(5.4-10.4)年、7.9(2.1-11.8)年、2.9(0.9-6.5)年(p=0.012)。
  • 15年无临床糖尿病Kaplan-Meier生存率分别为99.5%(95%CI 99.1, 99.7)、87.3%(95%CI 74.4, 94.0)和45.9%(95%CI 31.1, 59.6)(p<0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Screening for islet autoantibodies is an effective method for identifying individuals with pre-symptomatic (stage 1 and 2) type 1 diabetes. This approach offers a valuable opportunity for education and monitoring, which can help to reduce the severity of clinical manifestations at clinical onset (stage 3), including diabetic ketoacidosis. The aim of the study was to evaluate the progression to stage 3 and the incidence of diabetic ketoacidosis in relatives of individuals with type 1 diabetes screened and followed up at a single institution in Italy. METHODS: This was a single-centre observational study conducted at San Raffaele Hospital, Milan, Italy, within the international multisite TrialNet Natural History Study-Pathway to Prevention. First-degree (aged 1-45 years) and second-degree (aged 1-20 years) relatives were screened primarily for GADA, IAA and IA-2A. In the event of a positive result, subsequent testing was conducted for ICA and ZnT8A. Periodic autoantibody testing, metabolic monitoring and educational support were offered to all autoantibody-positive participants. Participants were screened between July 2005 and February 2020, with the latest update obtained between January 2023 and June 2024. RESULTS: In total, 4046 relatives were screened at a median (IQR) age of 17.6 (7.9-38.0) years. At first screening, 4.9% were found to be positive, with 3.1% having a single autoantibody and 1.8% multiple autoantibodies. Follow-up data were available for 78.5% of the participants, with a median (IQR) follow-up time of 9.9 (6.5-13.5) years. Progression to stage 3 was observed in 51 (1.6%) participants. Disease onset occurred in 0.4% of autoantibody-negative, 6.5% of single-positive and 43.1% of multiple-positive participants after a median (IQR) time of 7.8 (5.4-10.4), 7.9 (2.1-11.8) and 2.9 (0.9-6.5) years, respectively (p=0.012). The Kaplan-Meier survival free of clinical diabetes at 15 years was 99.5% (95% CI 99.1, 99.7), 87.3% (95% CI 74.4, 94.0) and 45.9% (95% CI 31.1, 59.6), respectively (p<0.001). At the time of disease onset, no occurrences of diabetic ketoacidosis were documented. Median (IQR) HbA1c was 64 (52-86) mmol/mol (8.0 [6.9-10.0]%) and median (IQR) venous pH at onset was 7.37 (7.35-7.39). Hospitalisation occurred in 22 paediatric participants, as part of standard practice for newly diagnosed patients at our institution aiming to provide disease education and insulin therapy optimisation. CONCLUSIONS/INTERPRETATION: The early identification of individuals at risk for type 1 diabetes through a single-centre approach, combining autoantibody screening and regular monitoring, completely prevented diabetes-associated ketoacidosis at disease onset in relatives of individuals with type 1 diabetes. TRIAL REGISTRATION: ClinicalTrials.gov NCT00097292.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Martinenghi S, Merolla A, Grogan P, et al. Prevention of diabetic ketoacidosis in relatives screened for islet autoantibodies and followed up in the TrialNet Pathway to Prevention study at a single institution in Italy. Diabetologia. 2025. PMID: 40439773. doi:10.1007/s00125-025-06461-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。